Yearth Bio ( www.yearthbio.com ), has demonstrated high-sensitivity capability on the early cancer detections based on WinMEMS' digital magnetic bead technology platform. Even 0.01% of tumor mutation genes and special methylation sites of tumor genes can be found in the liquid biopsys through these innovative technologies from both companies, including Yearth' cf-SUPER, cf-ROBUST and WinMEMS' EMMB System).The performance is close to the sensitivity of DDPCR (Droplet Digital PCR).